LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Scientific, Ethical, and Practical Considerations for the Testing and Disclosure of Alzheimer Disease Biomarkers

Photo from wikipedia

With the advent of promising, biomarker-directed, amyloid monoclonal antibody therapy for Alzheimer disease (AD),1 there is a need to understand the complex scientific, ethical, and practical implications related to biomarkers… Click to show full abstract

With the advent of promising, biomarker-directed, amyloid monoclonal antibody therapy for Alzheimer disease (AD),1 there is a need to understand the complex scientific, ethical, and practical implications related to biomarkers of neurodegenerative conditions,2 including how they can be used to determine the onset, progression, and subtype of these disorders. As the clinical use of AD biomarkers moves beyond specialized centers, and as they become widely used to identify, diagnose, and track the progression of dementia, it will be important to develop protocols to disclose the presence of AD biomarkers to patients.

Keywords: alzheimer disease; scientific ethical; practical considerations; considerations testing; ethical practical

Journal Title: Neurology
Year Published: 2023

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.